VIENNA — The highly selective oral Janus kinase (JAK) inhibitor SHR0302 (ivarmacitinib) enables more patients with active rheumatoid arthritis to meet American College of Rheumatology (ACR) response ...
Please provide your email address to receive an email when new articles are posted on . The study, comparing the 1% and 2% formulations of the drug, found the 2% topical to be effective. 62.5% of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback